GW Pharmaceuticals plc

GWPH


Canadian symbol: GWPH
US symbol: GWPH

Currency in USD

Valuation Measures

Market Cap (intraday) 53.78B
Enterprise Value 33.51B
Trailing P/E 120.09
Forward P/E 137.40
PEG Ratio (5 yr expected) 1-0.08
Price/Sales (ttm)9.62
Price/Book (mrq)5.55
Enterprise Value/Revenue 38.95
Enterprise Value/EBITDA 6-54.23

Trading Information

Stock Price History

Beta (5Y Monthly) 1.94
52-Week Change 3-23.71%
S&P500 52-Week Change 34.59%
52 Week High 3175.35
52 Week Low 367.98
50-Day Moving Average 3126.22
200-Day Moving Average 3110.36

Share Statistics

Avg Vol (3 month) 3345.61k
Avg Vol (10 day) 3274.03k
Shares Outstanding 531.08M
Float 30.36M
% Held by Insiders 11.12%
% Held by Institutions 183.33%
Shares Short (Jun. 14, 2020) 44.48M
Short Ratio (Jun. 14, 2020) 413.81
Short % of Float (Jun. 14, 2020) 4N/A
Short % of Shares Outstanding (Jun. 14, 2020) 414.46%
Shares Short (prior month May 14, 2020) 44.63M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec. 30, 2019
Most Recent Quarter (mrq)Mar. 30, 2020

Profitability

Profit Margin 8.42%
Operating Margin (ttm)-18.92%

Management Effectiveness

Return on Assets (ttm)-5.79%
Return on Equity (ttm)4.88%

Income Statement

Revenue (ttm)392.72M
Revenue Per Share (ttm)12.65
Quarterly Revenue Growth (yoy)207.40%
Gross Profit (ttm)284.13M
EBITDA -64.8M
Net Income Avi to Common (ttm)33.08M
Diluted EPS (ttm)1.07
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)500.94M
Total Cash Per Share (mrq)16.12
Total Debt (mrq)40.28M
Total Debt/Equity (mrq)5.63
Current Ratio (mrq)6.50
Book Value Per Share (mrq)23.03

Cash Flow Statement

Operating Cash Flow (ttm)-83.69M
Levered Free Cash Flow (ttm)7.89M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
GWPH
GW Pharmaceuticals plc
1 week ago
GWPH
GW Pharmaceuticals plc
2 weeks ago
GWPH
GW Pharmaceuticals plc
2 weeks ago
GWPH
GW Pharmaceuticals plc
2 weeks ago
GWPH
GW Pharmaceuticals plc
2 weeks ago
GWPH
GW Pharmaceuticals plc
2 weeks ago
GWPH
GW Pharmaceuticals plc
2 weeks ago
GWPH
GW Pharmaceuticals plc
3 weeks ago
GWPH
GW Pharmaceuticals plc
3 weeks ago
GWPH
GW Pharmaceuticals plc
3 weeks ago
GWPH
GW Pharmaceuticals plc
3 weeks ago
GWPH
GW Pharmaceuticals plc
3 weeks ago
GWPH
GW Pharmaceuticals plc
3 weeks ago
GWPH
GW Pharmaceuticals plc
4 weeks ago
GWPH
GW Pharmaceuticals plc
4 weeks ago
GWPH
GW Pharmaceuticals plc
1 month ago
GWPH
GW Pharmaceuticals plc
1 month ago
GWPH
GW Pharmaceuticals plc
1 month ago
GWPH
GW Pharmaceuticals plc
1 month ago
GWPH
GW Pharmaceuticals plc
1 month ago
GWPH
GW Pharmaceuticals plc
1 month ago
GWPH
GW Pharmaceuticals plc
1 month ago
GWPH
GW Pharmaceuticals plc
1 month ago
GWPH
GW Pharmaceuticals plc
1 month ago
GWPH
GW Pharmaceuticals plc
1 month ago
GWPH
GW Pharmaceuticals plc
1 month ago
GWPH
GW Pharmaceuticals plc
1 month ago
GWPH
GW Pharmaceuticals plc
1 month ago
GWPH
GW Pharmaceuticals plc
1 month ago
GWPH
GW Pharmaceuticals plc
2 months ago
GWPH
GW Pharmaceuticals plc
2 months ago
GWPH
GW Pharmaceuticals plc
2 months ago
GWPH
GW Pharmaceuticals plc
2 months ago
GWPH
GW Pharmaceuticals plc
2 months ago
GWPH
GW Pharmaceuticals plc
2 months ago
GWPH
GW Pharmaceuticals plc
2 months ago
GWPH
GW Pharmaceuticals plc
2 months ago
GWPH
GW Pharmaceuticals plc
2 months ago
GWPH
GW Pharmaceuticals plc
2 months ago
GWPH
GW Pharmaceuticals plc
2 months ago
GWPH
GW Pharmaceuticals plc
2 months ago
GWPH
GW Pharmaceuticals plc
2 months ago
GWPH
GW Pharmaceuticals plc
2 months ago
GWPH
GW Pharmaceuticals plc
2 months ago
GWPH
GW Pharmaceuticals plc
2 months ago
GWPH
GW Pharmaceuticals plc
3 months ago
GWPH
GW Pharmaceuticals plc
3 months ago
GWPH
GW Pharmaceuticals plc
3 months ago
GWPH
GW Pharmaceuticals plc
3 months ago
GWPH
GW Pharmaceuticals plc
3 months ago
GWPH
GW Pharmaceuticals plc
3 months ago
GWPH
GW Pharmaceuticals plc
3 months ago
GWPH
GW Pharmaceuticals plc
3 months ago
GWPH
GW Pharmaceuticals plc
3 months ago
GWPH
GW Pharmaceuticals plc
3 months ago
GWPH
GW Pharmaceuticals plc
3 months ago
GWPH
GW Pharmaceuticals plc
3 months ago
GWPH
GW Pharmaceuticals plc
3 months ago
GWPH
GW Pharmaceuticals plc
3 months ago
GWPH
GW Pharmaceuticals plc
3 months ago
GWPH
GW Pharmaceuticals plc
3 months ago
GWPH
GW Pharmaceuticals plc
3 months ago
GWPH
GW Pharmaceuticals plc
3 months ago
GWPH
GW Pharmaceuticals plc
3 months ago
GWPH
GW Pharmaceuticals plc
4 months ago
GWPH
GW Pharmaceuticals plc
4 months ago
GWPH
GW Pharmaceuticals plc
4 months ago
GWPH
GW Pharmaceuticals plc
4 months ago
GWPH
GW Pharmaceuticals plc
4 months ago
GWPH
GW Pharmaceuticals plc
4 months ago
GWPH
GW Pharmaceuticals plc
4 months ago
GWPH
GW Pharmaceuticals plc
4 months ago
GWPH
GW Pharmaceuticals plc
4 months ago
GWPH
GW Pharmaceuticals plc
4 months ago
GWPH
GW Pharmaceuticals plc
4 months ago
GWPH
GW Pharmaceuticals plc
4 months ago
GWPH
GW Pharmaceuticals plc
4 months ago
GWPH
GW Pharmaceuticals plc
5 months ago
GWPH
GW Pharmaceuticals plc
5 months ago
GWPH
GW Pharmaceuticals plc
5 months ago
GWPH
GW Pharmaceuticals plc
5 months ago
GWPH
GW Pharmaceuticals plc
5 months ago
GWPH
GW Pharmaceuticals plc
5 months ago
GWPH
GW Pharmaceuticals plc
6 months ago
GWPH
GW Pharmaceuticals plc
6 months ago
GWPH
GW Pharmaceuticals plc
6 months ago
GWPH
GW Pharmaceuticals plc
7 months ago
GWPH
GW Pharmaceuticals plc
7 months ago
GWPH
GW Pharmaceuticals plc
7 months ago
GWPH
GW Pharmaceuticals plc
7 months ago
GWPH
GW Pharmaceuticals plc
7 months ago
GWPH
GW Pharmaceuticals plc
7 months ago
GWPH
GW Pharmaceuticals plc
7 months ago
GWPH
GW Pharmaceuticals plc
7 months ago
GWPH
GW Pharmaceuticals plc
7 months ago
GWPH
GW Pharmaceuticals plc
7 months ago
GWPH
GW Pharmaceuticals plc
7 months ago
GWPH
GW Pharmaceuticals plc
7 months ago
GWPH
GW Pharmaceuticals plc
7 months ago
GWPH
GW Pharmaceuticals plc
8 months ago
GWPH
GW Pharmaceuticals plc
8 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
9 months ago
GWPH
GW Pharmaceuticals plc
10 months ago
GWPH
GW Pharmaceuticals plc
10 months ago
GWPH
GW Pharmaceuticals plc
10 months ago
GWPH
GW Pharmaceuticals plc
10 months ago
GWPH
GW Pharmaceuticals plc
10 months ago
GWPH
GW Pharmaceuticals plc
10 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
11 months ago
GWPH
GW Pharmaceuticals plc
12 months ago
GWPH
GW Pharmaceuticals plc
12 months ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago
GWPH
GW Pharmaceuticals plc
1 year ago

Currency in USD
Earnings EstimateCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
No. of Analysts4444
Avg. Estimate-0.65-0.81-2.483.42
Low Estimate-0.77-0.97-3.052.23
High Estimate-0.36-0.68-2.176.12
Year Ago EPS2.54-0.48-0.24-2.48
Revenue EstimateCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
No. of Analysts13131414
Avg. Estimate119.42M131.87M517.73M809.26M
Low Estimate112.4M121.77M477.73M642.59M
High Estimate129M153.96M586.5M1.17B
Year Ago Sales47.05MN/A311.33M517.73M
Sales Growth (year/est)153.80%N/A66.30%56.30%
Earnings History2019-06-292019-09-292019-12-302020-03-30
EPS Est.1.34-0.85-0.52-0.85
EPS Actual2.54-0.48-0.84-0.24
Difference1.20.37-0.320.61
Surprise %89.60%43.50%-61.50%71.80%
EPS TrendCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
Current Estimate-0.65-0.81-2.483.42
7 Days Ago-0.65-0.81-2.483.42
30 Days Ago-0.65-0.81-2.483.42
60 Days Ago-0.6-0.25-1.484.71
90 Days Ago-0.56-0.18-1.34.96
EPS RevisionsCurrent Qtr. (Jun 2020)Next Qtr. (Sep 2020)Current Year (2020)Next Year (2021)
Up Last 7 DaysN/AN/AN/AN/A
Up Last 30 DaysN/AN/AN/AN/A
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesGWPHIndustrySector(s)S&P 500
Current Qtr.-125.60%N/AN/AN/A
Next Qtr.-68.80%N/AN/AN/A
Current Year-933.30%N/AN/AN/A
Next Year237.90%N/AN/AN/A
Next 5 Years (per annum)613.80%N/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A


Insiders transactions are updated every hour.

Major Holders

Currency in USD
Breakdown
1.12%% of Shares Held by All Insider
83.33%% of Shares Held by Institutions
84.27%% of Float Held by Institutions
374Number of Institutions Holding Shares

Top Institutional Holders

HolderSharesDate Reported% OutValue
Capital Research Global Investors3,707,103Mar. 30, 202011.99%324,631,009
Franklin Resources, Inc2,371,792Mar. 30, 20207.67%207,697,825
Janus Henderson Group PLC1,720,352Mar. 30, 20205.57%150,651,224
Canada Pension Plan Investment Board1,500,000Mar. 30, 20204.85%131,355,000
Capital World Investors1,139,964Mar. 30, 20203.69%99,826,647
Citadel Advisors LLC976,986Mar. 30, 20203.16%85,554,664
M&G Investment Management Ltd810,280Mar. 30, 20202.62%70,956,219
Morgan Stanley800,265Mar. 30, 20202.59%70,079,206
Fred Alger Management, LLC758,297Mar. 30, 20202.45%66,404,068
Federated Hermes, Inc.753,432Mar. 30, 20202.44%65,978,040

Top Mutual Fund Holders

HolderSharesDate Reported% OutValue
Smallcap World Fund1,703,090Mar. 30, 20205.51%149,139,591
New Economy Fund (The)1,584,454Feb. 28, 20205.13%162,105,488
American Funds Insurance Ser-Global Small Capitalization Fund748,218Mar. 30, 20202.42%65,521,450
Janus Henderson Triton Fund523,270Mar. 30, 20201.69%45,822,753
Europacific Growth Fund518,362Mar. 30, 20201.68%45,392,960
Federated Hermes Kaufmann Fund500,000Apr. 29, 20201.62%50,070,000
ETF Managers Tr-EFTMG Alternative Harvest ETF462,247Mar. 30, 20201.50%40,478,969
Franklin Strategic Series-Franklin Biotechnology Discove421,600Apr. 29, 20201.36%42,219,024
Growth Fund Of America Inc384,854Mar. 30, 20201.24%33,701,664
Janus Henderson Global Life Sciences Fund360,417Mar. 30, 20201.17%31,561,716
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by GW Pharmaceuticals plc


GW Pharmaceuticals Presents Nabiximols U.S. Development and Commercial Strategy

GW Pharmaceuticals Presents Nabiximols U.S. Development and Commercial Strategy

 - Potential accelerated pathway to NDA submission - - Clinical program of five Phase 3 trials provides multiple options for NDA submission, as early as 2021 -- Webcast featuring a range of guest speakers to be held today from 10:00am-12:00pm EDT -CARLSBAD, Calif., June 30, 2020 -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or ... Read More...
GW Pharmaceuticals announces that EPIDYOLEX® (cannabidiol) has been reclassified by the UK Home Office as a Schedule 5 drug

GW Pharmaceuticals announces that EPIDYOLEX® (cannabidiol) has been reclassified by the UK Home Office as a Schedule 5 drug

GW’s cannabis-based medicine rescheduled following approval by the European Medicines Agency (EMA) and an independent assessment by the Advisory Council on the Misuse of Drugs (ACMD)Burden on patients, their families and healthcare professionals eased due to the reduction in controlled drug requirements   LONDON, June 24, 2020 -- GW Pharm... Read More...
GW Pharmaceuticals to Host Virtual Investor Event on Its Nabiximols U.S. Development Program and Market Opportunity

GW Pharmaceuticals to Host Virtual Investor Event on Its Nabiximols U.S. Development Program and Market Opportunity

LONDON and CARLSBAD, Calif., June 04, 2020 -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW or the Company), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will host a virtual event for investors to provide a review of the U.S. development program and ma... Read More...
GW Pharmaceuticals plc Reports First Quarter 2020 Financial Results and Operational Progress

GW Pharmaceuticals plc Reports First Quarter 2020 Financial Results and Operational Progress

- Total revenue of $120.6 million - - Total Epidiolex® net product sales of $116.1 million - - Conference call today at 4:30 p.m. EDT –LONDON and CARLSBAD, Calif., May 11, 2020 -- GW Pharmaceuticals plc (Nasdaq: GWPH), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announces ... Read More...
GW Pharmaceuticals to Present at the Bank of America Healthcare Conference 2020

GW Pharmaceuticals to Present at the Bank of America Healthcare Conference 2020

LONDON and CARLSBAD, Calif., May 01, 2020 -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer, will present a business update at the Bank of America He... Read More...
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the First Quarter Ending March 31st, 2020 and Host Conference Call on May 11th, 2020

GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the First Quarter Ending March 31st, 2020 and Host Conference Call on May 11th, 2020

CARLSBAD, Calif., April 21, 2020 -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on May 11th, 2020 its financial results for the first quarter ending March ... Read More...
GW Pharmaceuticals plc and Its U.S. Subsidiary Greenwich Biosciences, Inc. Announce That EPIDIOLEX® (cannabidiol) Oral Solution Has Been Descheduled And Is No Longer A Controlled Substance

GW Pharmaceuticals plc and Its U.S. Subsidiary Greenwich Biosciences, Inc. Announce That EPIDIOLEX® (cannabidiol) Oral Solution Has Been Descheduled And Is No Longer A Controlled Substance

- Descheduling will enable prescribing free of the previous Schedule V requirements -CARLSBAD, Calif., April 06, 2020 -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid platform,... Read More...
GW Pharmaceuticals and Greenwich Biosciences Announce FDA Acceptance of sNDA Filing with Priority Review for EPIDIOLEX® (cannabidiol) in the Treatment of Seizures Associated with Tuberous Sclerosis Complex

GW Pharmaceuticals and Greenwich Biosciences Announce FDA Acceptance of sNDA Filing with Priority Review for EPIDIOLEX® (cannabidiol) in the Treatment of Seizures Associated with Tuberous Sclerosis Complex

CARLSBAD, Calif., March 31, 2020 -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, Inc., today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Prio... Read More...
GW Pharmaceuticals submits Type II Variation Application to the European Medicines Agency (EMA) to expand the use of EPIDYOLEX®, (cannabidiol) oral solution, for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC)

GW Pharmaceuticals submits Type II Variation Application to the European Medicines Agency (EMA) to expand the use of EPIDYOLEX®, (cannabidiol) oral solution, for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC)

LONDON, March 13, 2020 -- GW Pharmaceuticals plc (Nasdaq: GWPH) (“GW”, “the Company” or “the Group”), a world leader in discovering, developing and commercialising cannabinoid prescription medicines, today announces the submission of a Type II Variation Application to the European Medicines Agency (EMA) seeking approval of EPIDYOLEX®, (ca... Read More...
JAMA Neurology Publishes Results from Positive Phase 3 Trial of EPIDIOLEX® (cannabidiol) oral solution in Children with Seizures Associated with Dravet Syndrome

JAMA Neurology Publishes Results from Positive Phase 3 Trial of EPIDIOLEX® (cannabidiol) oral solution in Children with Seizures Associated with Dravet Syndrome

CARLSBAD, Calif., March 02, 2020 -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, announced today that JAMA Neurology has published results from the second posi... Read More...
GW Pharmaceuticals regains exclusive commercialisation rights to Sativex® (nabiximols) in the UK from Bayer

GW Pharmaceuticals regains exclusive commercialisation rights to Sativex® (nabiximols) in the UK from Bayer

CAMBRIDGE, United Kingdom and READING, United Kingdom, March 02, 2020 -- GW Pharmaceuticals plc (GW) and Bayer plc, the life science company, today announce that GW will regain exclusive UK commercialisation rights for Sativex® (delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)) from Bayer.Sativex, often known by the USAN name nabi... Read More...
GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2019 Financial Results and Operational Progress

GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2019 Financial Results and Operational Progress

- Total revenue of $109.1 million for the fourth quarter and $311.3 million for the full year -- Total Epidiolex® net product sales of $104.5 million for the fourth quarter and $296.4 million for the first full year of sales - - Conference call today at 4:30 p.m. EST - LONDON and CARLSBAD, Calif., Feb. 25, 2020 -- GW Pharmaceuticals plc (... Read More...
GW Pharmaceuticals to Present at the Cowen 40th Annual Healthcare Conference

GW Pharmaceuticals to Present at the Cowen 40th Annual Healthcare Conference

LONDON and CARLSBAD, Calif., Feb. 24, 2020 -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer, will present a business update at the Cowen 40th Annual... Read More...
GW Pharmaceuticals and Greenwich Biosciences Submit Supplemental New Drug Application to U.S. FDA for Epidiolex® (cannabidiol) for the Treatment of Tuberous Sclerosis Complex

GW Pharmaceuticals and Greenwich Biosciences Submit Supplemental New Drug Application to U.S. FDA for Epidiolex® (cannabidiol) for the Treatment of Tuberous Sclerosis Complex

LONDON and CARLSBAD, Calif., Feb. 03, 2020 -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, Inc., announced today that it has submitted a supplemental New D... Read More...
GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales

GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales

- Total preliminary net product sales of approximately $108 million for the fourth quarter and approximately $309 million for the full year - - Total Epidiolex® preliminary net product sales of approximately $104 million for the fourth quarter and approximately $296 million for the first full year of sales -LONDON and CARLSBAD, Calif., Ja... Read More...
GW Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

GW Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference

LONDON and CARLSBAD, Calif., Jan. 07, 2020 -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer, will present a business update at the 38th Annual J.P... Read More...
Greenwich Biosciences, a GW Pharmaceuticals Company, Presents New Data for EPIDIOLEX® (cannabidiol) in Patients with Tuberous Sclerosis Complex (TSC) at the American Epilepsy Society Annual Meeting

Greenwich Biosciences, a GW Pharmaceuticals Company, Presents New Data for EPIDIOLEX® (cannabidiol) in Patients with Tuberous Sclerosis Complex (TSC) at the American Epilepsy Society Annual Meeting

CARLSBAD, Calif., Dec. 07, 2019 -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences, today presented new data from a Phase 3 clinical trial of EPIDIOLEX® (cannabidiol or CBD) oral solution, CV i... Read More...
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting

GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data on EPIDIOLEX® (cannabidiol) Oral Solution at the American Epilepsy Society Annual Meeting

LONDON and CARLSBAD, Calif., Dec. 05, 2019 -- GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with U.S. subsidiary Greenwich Biosciences announced today that a variety of data, including results from completed Phase 3 trials of EPIDIOLE... Read More...
GW Pharmaceuticals to Present at Upcoming Investor Conferences

GW Pharmaceuticals to Present at Upcoming Investor Conferences

CARLSBAD, Calif., Nov. 22, 2019 -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer, will present ... Read More...
GW Pharmaceuticals receives positive NICE recommendation for EPIDYOLEX® (cannabidiol) oral solution for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy

GW Pharmaceuticals receives positive NICE recommendation for EPIDYOLEX® (cannabidiol) oral solution for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy

GW also welcomes the positive guideline recommendation for Sativex® (nabiximols) for the treatment of spasticity due to multiple sclerosis as part of NICE’s evaluation of cannabis-based medicinal products (CBMPs)Cannabidiol oral solution and nabiximols are the first and only plant-derived cannabis-based medicines to be routinely reimburse... Read More...
GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Third Quarter Ended September 30, 2019

GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Third Quarter Ended September 30, 2019

- Epidiolex U.S. year to date net sales of $188.0 million, including Q3 net sales of $86.1 million - - Conference call today at 4:30 p.m. ET -CARLSBAD, Calif., Nov. 05, 2019 -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the discovery, development and commercialization of cannabinoid prescripti... Read More...
GW Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2nd, 2019

GW Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference on Wednesday, October 2nd, 2019

CARLSBAD, Calif., Sept. 24, 2019 -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the development and commercialization of cannabinoid prescription medicines, today announced that Scott Giacobello, GW’s Chief Financial Officer and Stephen Schultz... Read More...
GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy

GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy

Cannabidiol oral solution is the first plant-derived cannabis-based medicine to be approved by the European Medicines Agency (EMA)Cannabidiol oral solution contains highly purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the “high” associated with cannabis LONDON and CARLSBAD, Calif., Sept. 23, 2019 -- GW Pharmaceuticals p... Read More...
GW Pharmaceuticals to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on Wednesday, September 11th, 2019

GW Pharmaceuticals to Present at the Morgan Stanley 17th Annual Global Healthcare Conference on Wednesday, September 11th, 2019

CARLSBAD, Calif., Sept. 04, 2019 -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer will present ... Read More...
GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX™ (cannabidiol oral solution) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy

GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX™ (cannabidiol oral solution) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy

If approved cannabidiol oral solution will be the first plant-derived cannabis-based medicine to be approved in Europe for the treatment of any form of epilepsyGW’s cannabidiol oral solution contains highly purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the “high” associated with cannabis LONDON and CARLSBAD, Calif., Jul... Read More...
GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Period Ending June 30, 2019 and Host Conference Call on August 6, 2019

GW Pharmaceuticals plc to Report Financial Results and Operational Progress for the Period Ending June 30, 2019 and Host Conference Call on August 6, 2019

LONDON, July 23, 2019 -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on August 6, 2019 its financial results for the quarter ending June 30, 2019. GW will ... Read More...
GW Pharmaceuticals to Present at the 40th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11th, 2019

GW Pharmaceuticals to Present at the 40th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11th, 2019

CARLSBAD, Calif., June 04, 2019 -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Stephen Schultz, GW’s Vice President of Investor Relation... Read More...
GW Pharmaceuticals to Present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 15, 2019

GW Pharmaceuticals to Present at the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 15, 2019

LONDON, May 09, 2019 -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that Justin Gover, GW’s Chief Executive Officer, will present at the Bank... Read More...
GW Pharmaceuticals Reports Positive Phase 3 Pivotal Trial Results for EPIDIOLEX® (cannabidiol) Oral Solution in Patients with Seizures Associated With Tuberous Sclerosis Complex

GW Pharmaceuticals Reports Positive Phase 3 Pivotal Trial Results for EPIDIOLEX® (cannabidiol) Oral Solution in Patients with Seizures Associated With Tuberous Sclerosis Complex

- Achieved primary efficacy measure with both EPIDIOLEX doses as compared to placebo - - Represents the fifth consecutive positive Phase 3 pivotal trial for EPIDIOLEX - - Expect to file sNDA in Q4 2019 -  CARLSBAD, Calif., May 06, 2019 -- GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, th... Read More...
GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2019

GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2019

- Epidiolex U.S. Q1 net sales of $33.5m - - Positive Phase 3 pivotal results in Tuberous Sclerosis Complex, sNDA submission expected in Q4 2019 - - Conference call today at 4:30 p.m. EDT -CARLSBAD, Calif., May 06, 2019 -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development and ... Read More...
GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data on Epidiolex® (cannabidiol) oral solution, CV at the 2019 American Academy of Neurology Annual Meeting

GW Pharmaceuticals and U.S. Subsidiary Greenwich Biosciences to Present Data on Epidiolex® (cannabidiol) oral solution, CV at the 2019 American Academy of Neurology Annual Meeting

CARLSBAD, Calif., May 02, 2019 -- GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), the world leader in the development and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, will present data from the pivotal Phase 3 trials of Epidiolex® (cannabidiol) or... Read More...
Coming Soon.

Delayed data (1h)


Share this page